ZA201505093B - Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis - Google Patents
Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosisInfo
- Publication number
- ZA201505093B ZA201505093B ZA2015/05093A ZA201505093A ZA201505093B ZA 201505093 B ZA201505093 B ZA 201505093B ZA 2015/05093 A ZA2015/05093 A ZA 2015/05093A ZA 201505093 A ZA201505093 A ZA 201505093A ZA 201505093 B ZA201505093 B ZA 201505093B
- Authority
- ZA
- South Africa
- Prior art keywords
- dimethylpropan
- aminium
- atherosclerosis
- carboxy
- ethyl
- Prior art date
Links
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198627 | 2012-12-20 | ||
| PCT/EP2013/077291 WO2014096133A1 (en) | 2012-12-20 | 2013-12-19 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201505093B true ZA201505093B (en) | 2016-04-28 |
Family
ID=47458734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/05093A ZA201505093B (en) | 2012-12-20 | 2015-07-15 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN104869988B (es) |
| AR (1) | AR094084A1 (es) |
| BR (1) | BR112015014161B1 (es) |
| CA (1) | CA2895574C (es) |
| CU (1) | CU20150067A7 (es) |
| JO (1) | JO3117B1 (es) |
| MX (1) | MX362762B (es) |
| PE (1) | PE20151587A1 (es) |
| TN (1) | TN2015000236A1 (es) |
| WO (1) | WO2014096133A1 (es) |
| ZA (1) | ZA201505093B (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149654A1 (en) * | 2009-06-25 | 2010-12-29 | Grindeks, A Joint Stock Company | Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt |
| JP5706409B2 (ja) * | 2009-06-25 | 2015-04-22 | テトラ，エスイーアー | 新規なサリチル酸塩 |
| LV14345B (lv) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| US20140088125A1 (en) * | 2011-04-27 | 2014-03-27 | Jsc Grindeks | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
-
2013
- 2013-12-11 JO JOP/2013/0362A patent/JO3117B1/ar active
- 2013-12-18 AR ARP130104820A patent/AR094084A1/es unknown
- 2013-12-19 MX MX2015008138A patent/MX362762B/es active IP Right Grant
- 2013-12-19 PE PE2015000876A patent/PE20151587A1/es not_active Application Discontinuation
- 2013-12-19 BR BR112015014161-7A patent/BR112015014161B1/pt active IP Right Grant
- 2013-12-19 CA CA2895574A patent/CA2895574C/en active Active
- 2013-12-19 CN CN201380066810.0A patent/CN104869988B/zh active Active
- 2013-12-19 WO PCT/EP2013/077291 patent/WO2014096133A1/en active Application Filing
-
2015
- 2015-06-01 TN TNP2015000236A patent/TN2015000236A1/fr unknown
- 2015-06-19 CU CUP2015000067A patent/CU20150067A7/es unknown
- 2015-07-15 ZA ZA2015/05093A patent/ZA201505093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20150067A7 (es) | 2016-01-29 |
| CN104869988B (zh) | 2017-07-28 |
| MX2015008138A (es) | 2016-04-25 |
| CA2895574A1 (en) | 2014-06-26 |
| BR112015014161B1 (pt) | 2021-02-17 |
| AR094084A1 (es) | 2015-07-08 |
| JO3117B1 (ar) | 2017-09-20 |
| MX362762B (es) | 2019-02-06 |
| TN2015000236A1 (en) | 2016-10-03 |
| BR112015014161A2 (pt) | 2017-07-11 |
| CA2895574C (en) | 2019-11-26 |
| WO2014096133A1 (en) | 2014-06-26 |
| PE20151587A1 (es) | 2015-12-05 |
| CN104869988A (zh) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2022043I1 (en) | Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride | |
| NO2022010I1 (no) | ripretinib, or a pharmaceutically acceptable salt thereof | |
| IL234628A0 (en) | Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs | |
| IL231386A (en) | Pyrazolequinoline derivatives, their preparation and medical use | |
| EP2806931A4 (en) | MODULAR PULMONARY TREATMENT SYSTEM | |
| AP2015008510A0 (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| IL237068A (en) | 1,3-dioxanomorphides and 1,3-dioxanocodides | |
| ZA201300957B (en) | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and use thereof | |
| EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
| EP2906208A4 (en) | THERAPEUTIC TREATMENT | |
| PL2831055T3 (pl) | Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie | |
| IL251974A0 (en) | Antifibrosis compounds and their uses | |
| NO2022002I1 (no) | tasipimidine optionally in the form of a pharmaceutically acceptable salt thereof, in particular tasipimidine sulfate | |
| EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| EP2861244A4 (en) | TREATMENT OF SLEEP APNEA | |
| EP2837627A4 (en) | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | |
| HK1196535A1 (zh) | 鹽及醫藥用途 | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| HUE041320T2 (hu) | 1,3-Specifikus intraészterezés | |
| IL232239A0 (en) | Medical use | |
| GB201215502D0 (en) | Medical use | |
| IL228891A (en) | 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease | |
| EP2817004A4 (en) | BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES | |
| ZA201505093B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis | |
| GB2503003B (en) | Processing titanium dioxide |